The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis-Reference-Cited by-同舟云学术

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis

Published:2005-04 Issue:4 Volume:149 Page:675-680
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Pamukcu Burak,Oflaz Huseyin,Nisanci Yilmaz

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference34 articles.

1. The effect of chronic platelet inhibition with low dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from Physicians Health Study;Ridker;Am. Heart J.,1991

2. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients;BMJ,1994

3. Profile and prevalence of aspirin resistance in patients with cardiovascular disease;Gum;Am. J. Cardiol.,2001

4. Platelet glycoprotein IIb/IIIa PlA2 homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men. The Copenhagen City Heart Study;Bojesen;J. Am. Coll. Cardiol.,2003

5. Glycoprotein IIIa PlA1/A2 polymorphism and sudden cardiac death;Mikkelsson;J. Am. Coll. Cardiol.,2000

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High on-aspirin treatment platelet reactivity and restenosis after percutaneous coronary intervention: results of the Intracoronary Stenting and Antithrombotic Regimen-ASpirin and Platelet Inhibition (ISAR-ASPI) Registry;Clinical Research in Cardiology;2023-02-14

2. Pharmacogenomics in cardiovascular diseases;Pharmacogenomics;2023

3. Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention;SAGE Open Medicine;2021-01

4. CYP2C19*2, CYP2C19*17 and ITGB3 (PlA1/A2) polymorphisms and resulting therapeutic alterations of clopidogrel and aspirin: A clinical screening among CVD patients who undergone PCI;2020-10-04

5. Association among PlA1/A2 gene polymorphism, laboratory aspirin resistance and clinical outcomes in patients with coronary artery disease: An updated meta-analysis;Scientific Reports;2019-09-11